Phase 2 APL Clinical Trials
65 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 65 trials
Recruiting
Phase 2
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Paroxysmal Nocturnal Hemoglobinuria, PNHSevere Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
MDS (Myelodysplastic Syndrome)Severe Aplastic Anemia
National Heart, Lung, and Blood Institute (NHLBI)120 enrolled2 locationsNCT01174108
Recruiting
Phase 1Phase 2
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Myelodysplastic Syndrome (MDS)Severe Aplastic AnemiaHypo-Plastic MDS
National Heart, Lung, and Blood Institute (NHLBI)37 enrolled1 locationNCT03173937
Recruiting
Phase 2
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Metastatic Breast CancerHER2-negative Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute36 enrolled3 locationsNCT05660083
Recruiting
Phase 2
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 1Phase 2
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
Arkansas Children's Hospital Research Institute24 enrolled4 locationsNCT07252050
Recruiting
Phase 2Phase 3
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Metabolic SyndromeSpinal Cord InjuryTraumatic Spinal Cord Injury+1 more
Northwell Health60 enrolled3 locationsNCT07625332
Recruiting
Phase 1Phase 2
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Glioblastoma MultiformeAnaplastic Astrocytoma
Northwell Health54 enrolled1 locationNCT01269853
Recruiting
Phase 2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Phase 2
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 2
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
High Grade GliomaAnaplastic Astrocytoma
Ashish Shah33 enrolled1 locationNCT06264388
Recruiting
Phase 2
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Anaplastic Large Cell Lymphoma, ALK-Positive
New York Medical College20 enrolled1 locationNCT07013565
Recruiting
Phase 1Phase 2
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
Severe Aplastic AnemiaSingle Lineage Cytopenias, T-LGLHypoplastic MDS
National Heart, Lung, and Blood Institute (NHLBI)145 enrolled1 locationNCT05998408
Recruiting
Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms TumorRecurrent Kidney Wilms TumorStage II Kidney Wilms Tumor+2 more
Children's Oncology Group256 enrolled204 locationsNCT04322318
Recruiting
Phase 2
Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354
Recruiting
Phase 2
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Aplastic Anemia
Assistance Publique - Hôpitaux de Paris52 enrolled26 locationsNCT06646497
Recruiting
Phase 2
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
Severe Aplastic Anemia
Northside Hospital, Inc.20 enrolled2 locationsNCT02828592
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 2
Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA
MDS (Myelodysplastic Syndrome)Aplastic Anemia (AA)
The First Affiliated Hospital of Soochow University66 enrolled1 locationNCT07400341
Recruiting
Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Myelodysplastic SyndromeAplastic Anemiade Novo Myelodysplastic Syndrome+1 more
M.D. Anderson Cancer Center140 enrolled1 locationNCT01624805